<DOC>
	<DOCNO>NCT02445703</DOCNO>
	<brief_summary>The purpose study compare immunogenicity safety three different immunization schedule inactivate hepatitis A vaccine ( HAV ) and/ combine hepatitis A B vaccine ( HABV ) healthy Chinese infant .</brief_summary>
	<brief_title>Comparison Immunization Schedules Inactivated Hepatitis A Vaccine Combined Hepatitis A Hepatitis B Vaccine</brief_title>
	<detailed_description>This study randomize double-blind , single-center , phase IV clinical trial . The purpose study compare immunogenicity safety three different immunization schedule inactivate hepatitis A vaccine ( HAV ) and/ combine hepatitis A B vaccine ( HABV ) healthy Chinese infant 18 24 month old . The subject randomly assign 3 group . Subjects group 1 receive 2 dos HAV 6-month interval ( day 0 month 6 ) ; subject group 2 receive 1 dose HAV day 0 1 dose HABV month 6 ; subject group 3 receive 2 dos HABV 6-month interval ( day 0 month 6 ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infant 18 24 month old ; Have receive hepatitis A vaccine ; Completed hepatitis B vaccine full immunization schedule ; Written consent guardian participant ; Exclusion Criteria First Injection : History allergy vaccine ( ) , history serious adverse reaction vaccination , urticaria , dyspnea , angioneurotic edema , abdominal pain ; Autoimmune disease immunodeficiency ; Any acute disease make condition person unsuitable vaccination Administration live attenuate vaccine within 14 day prior injection ; Administration subunit vaccine inactivate vaccine within 7 day prior injection ; Administration treatment immunosuppressant ( e.g. , corticosteroid ) within 1 month prior injection , plan treatment study ; Body temperature &gt; 37.0 °C injection ; Based evaluation investigator , factor indicate person unsuitable study ; Exclusion Criteria Second Injection : Any acute infectious disease , body temperature &gt; 38.5 °C acute attack chronic disease within 3 day prior second injection ; Administration blood product investigational drug study ; Occurrence adverse event grade 3 high event relate first injection ; The investigator Ethic Committee decide subject exclude ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>